Return migration in Italy: what do we know?

Return migration is the positive counterpart of brain drain. Human capital accumulation increases in a country if skilled agents go back home after a period spent working abroad. Effects of brain drain in Italy could be negative as highly skilled migrants decide not to come back to their native country. Our simple model shows that if preference for home consumption is balanced by career opportunities and life-style conditions, agents leave Italy and prefer to remain abroad. Data support and policy implications are provided.Return migration; brain drain.

Leukocyte Receptor Tyrosine Kinase interacts with secreted midkine to promote survival of migrating neural crest cells

Neural crest cells migrate long distances throughout the embryo and rely on extracellular signals that attract, repel and/or stimulate survival to ensure proper contribution to target derivatives. Here, we show that leukocyte receptor tyrosine kinase (LTK), an ALK-type receptor tyrosine kinase, is expressed by neural crest cells during early migratory stages in chicken embryos. Loss of LTK in the cranial neural crest impairs migration and results in increased levels of apoptosis. Conversely, midkine, previously proposed as a ligand for ALK, is secreted by the non-neural ectoderm during early neural crest migratory stages and internalized by neural crest cells in vivo. Similar to loss of LTK, loss of midkine reduces survival of the migratory neural crest. Moreover, we show by proximity ligation and co-immunoprecipitation assays that midkine binds to LTK. Taken together, these results suggest that LTK in neural crest cells interacts with midkine emanating from the non-neural ectoderm to promote cell survival, revealing a new signaling pathway that is essential for neural crest development

The rare case of positive FDG-positron emission tomography for giant cavernous hemangioma of the liver

Hemangioma is the most common benign liver tumor and the second most common liver tumor after metastases. Large hemangiomas are often heterogeneous. When they exceed 4 cm in diameter, they are termed giant hemangiomas. These giant hemangiomas often present heterogeneous patterns. These heterogeneous appearances are shown because of intratumoral changes due to several degenerative phenomena. PET/CT is reported to be useful for the differentiation of benign from malignant liver lesions. We report the case of a large hepatic hemangioma characterized by high FDG uptake

Interleukin-34 promotes tumorigenic signals for colon cancer cells

Colorectal carcinoma (CRC) is one of the most common forms of malignancy in the Western world. Accumulating evidence indicates that colon carcinogenesis is tightly controlled by tumour-associated immune cells and stromal cells, which can either stimulate or suppress CRC cell growth and survival, mainly via the production of cytokines. Interleukin-34 (IL-34), a cytokine known to regulate mainly monocyte/macrophage survival and function, is highly produced within the CRC microenvironment by several cell types, including cancer cells, tumour-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), and regulates the pro-tumoural functions of such cells. In this article, we summarize the available data supporting the multiple effects of IL-34 in human CRC

Involvement of smad7 in inflammatory diseases of the gut and colon cancer

In physiological conditions, the human intestinal mucosa is massively infiltrated with various subsets of immune cells, the activity of which is tightly regulated by several counter-regulatory factors. One of these factors is transforming growth factor-beta 1 (TGF-beta 1), a cytokine produced by multiple cell types and targeting virtually all the intestinal mucosal cells. Binding of TGF-beta 1 to its receptors triggers Smad2/3 signaling, thus culminating in the attenuation/suppression of immune-inflammatory responses. In patients with Crohn's disease and patients with ulcerative colitis, the major human inflammatory bowel diseases (IBD), and in mice with IBD-like colitis, there is defective TGF-beta 1/Smad signaling due to high levels of the intracellular inhibitor Smad7. Pharmacological inhibition of Smad7 restores TGF-beta 1 function, thereby reducing inflammatory pathways in patients with IBD and colitic mice. On the other hand, transgenic over-expression of Smad7 in T cells exacerbates colitis in various mouse models of IBD. Smad7 is also over-expressed in other inflammatory disorders of the gut, such as refractory celiac disease, necrotizing enterocolitis and cytomegalovirus-induced colitis, even though evidence is still scarce and mainly descriptive. Furthermore, Smad7 has been involved in colon carcinogenesis through complex and heterogeneous mechanisms, and Smad7 polymorphisms could influence cancer prognosis. In this article, we review the data about the expression and role of Smad7 in intestinal inflammation and cancer

Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

The ongoing COVID-19 pandemic has raised concerns about the risk of SARS-CoV-2 infection in patients with Crohn's disease (CD) and patients with ulcerative colitis (UC) taking immunosuppressants or biologics. We conducted a systematic review and meta-analysis to assess the risk of respiratory infections in patients with inflammatory bowel disease (IBD) treated with vedolizumab. We searched PubMed, EMBASE and Scopus to identify randomized controlled trials (RCT) comparing vedolizumab to placebo in patients with IBD. Outcomes were the rate of respiratory tract infections (RTI), upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI) among patients receiving vedolizumab as compared with placebo. Pooled rates were reported as Odds Ratios (OR) with 95% Confidence Interval (CI). Eight RCT involving 3,287 patients (1873 CD and 1415 UC) were analyzed; 2,493 patients received vedolizumab and 794 received placebo. The rates of RTI and URTI were statistically higher in vedolizumab-treated patients compared to placebo [OR = 1.63; 95% CI (1.07-2.49); OR = 1.64 95% CI (1.07-2.53) respectively]. UC patients, but not CD patients, receiving vedolizumab had a higher risk to develop RTI and URTI [OR = 1.98; 95% CI (1.41-2.77); OR = 2.02; 95% CI (1.42-2.87)] compared to placebo-treated patients. The number of LRTI was small in both treatment groups. Data confirm the good safety profile of vedolizumab even though RTI were more frequent in patients receiving vedolizumab and the risk of URTIs was significantly higher in patients with UC

Mind the gap: IR and the challenge of international politics

The discipline of International Relations (IR) for a long time of its history has developed in the form of Great Debates that involved competing paradigms and schools. More recently, it has been described as a cacophony of voices unable to communicate among themselves, but also incapable to provide keys to understand an ever more complex reality. This collection aims at evaluating the heuristic value of a selection of traditional paradigmsrealism and liberalism), schools (constructivism), and subdisciplines (security studies and international political economy) so as to assess the challenges before IR theory today and the ability of the discipline to provide tools to make the changed world still intelligible

Diagnóstico imagenológico en el Síndrome de Abernethy

El shunt portosistémico congénito (SPSC) o Síndrome de Abernethy es una patología muy poco frecuente, descrita por primera vez en 1793 por John Abernethy. Existen dos tipos de SPSC: tipo I (shunt terminolateral) en el que existe ausencia total de flujo portal intrahepático y tipo II (shunt laterolateral) con flujo portal parcialmente conservado. Los SPSC tipo I se presentan predominantemente en el sexo femenino y se asocian con múltiples malformaciones como poliesplenia, malrotación y cardiopatía. Los tipo II, aún más raros, afectan a ambos sexos y no suelen presentar malformaciones asociadas. La encefalopatía hepática es una complicación posible en ambos tipos de SPSC en la edad adulta. El trasplante hepático es el único tratamiento descrito para el SPSC tipo I cuando se vuelve sintomático, mientras que la ligadura del shunt es una opción quirúrgica para el tipo II. Objetivo: Presentar el diagnóstico imagenológico en un paciente adulto con Síndrome de Abernethy tipo 1B.Congenital portosystemic shunt (CEPS) or Abernethy Syndrome is a rare condition that was first reported by John Abernethy in 1793. Two types of CEPS are described: type I (side to end anastomosis) or congenital absence of the portal vein, and type II (side to side anastomosis) with portal vein supply partially conserved. Type I CEPS is usually seen in girls and associates multiple malformations as polysplenia, malrotation, and cardiac anomalies. Type II is even rarer with no sex preference and no malformations associated. Hepatic encephalopathy is a common complication of both types in adulthood. Liver transplantation is the only effective treatment for symptomatic type I CEPS. A therapeutic approach for type II could be surgical closure of the shunt. Objective: To present the imagenological diagnosis an adult patient with Abernethy Syndrome type 1B.Fil: Pérez Monteleone, Leonardo E.. Hospital Luis Lagomaggiore (Mendoza, Argentina). Servicio de Cirugía General.Fil: Manzino, Ricardo. Hospital Luis Lagomaggiore (Mendoza, Argentina). Servicio de Cirugía General.Fil: Gutierrez, Mario. Hospital Luis Lagomaggiore (Mendoza, Argentina). Servicio de Cirugía General.Fil: Bufaliza, Jorge. Hospital Luis Lagomaggiore (Mendoza, Argentina). Servicio de Cirugía General.Fil: Correa, Roberto. Hospital Luis Lagomaggiore (Mendoza, Argentina). Servicio de Cirugía General